drug_type
RELEVANT_DRUG
intervention_type
Biological (Cellular Gene Therapy; CAR T cells)
drug_description
Autologous dual-target chimeric antigen receptor (CAR) T-cell therapy in which a patient’s T cells are genetically engineered to co-express CARs targeting BCMA and CD19, enabling direct antigen recognition and CAR-mediated activation and cytotoxic killing of malignant plasma cells and B-lineage cells; designed to reduce antigen escape in relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to co-express chimeric antigen receptors targeting BCMA and CD19. Binding to these antigens on malignant plasma cells and B-lineage cells triggers CAR-mediated activation, proliferation, and cytotoxic killing, with dual targeting designed to reduce antigen escape in relapsed/refractory multiple myeloma.
drug_name
KQ-2003 CAR T-cells
nct_id_drug_ref
NCT06223646